Last updated: August 4, 2026
BTG International Limited v. Amneal Pharmaceuticals LLC, No. 2:15-cv-05909, was a Hatch-Waxman patent case concerning generic abiraterone acetate, the active ingredient in Zytiga. The dispute centered on U.S. Patent No. 8,822,438, which claimed treatment of prostate cancer with abiraterone acetate in combination with prednisone. The Federal Circuit ultimately upheld the patent’s validity and infringement findings, preserving BTG’s method-of-use patent against Amneal’s ANDA challenge. BTG International Ltd. v. Amneal Pharmaceuticals LLC, 923 F.3d 1063 (Fed. Cir. 2019).
What drug and patents were involved in BTG International v. Amneal?
The case involved abiraterone acetate tablets, marketed by Janssen Biotech as Zytiga. Abiraterone acetate inhibits androgen biosynthesis and is used with prednisone for certain patients with advanced prostate cancer.
| Item |
Detail |
| Brand drug |
Zytiga |
| Active ingredient |
Abiraterone acetate |
| Dosage form |
Oral tablets |
| Reference applicant |
Janssen Biotech, Inc. |
| Patent plaintiff |
BTG International Limited |
| Generic applicant |
Amneal Pharmaceuticals LLC |
| District court |
U.S. District Court for the District of New Jersey |
| Civil action |
No. 2:15-cv-05909 |
| Principal patent |
U.S. Patent No. 8,822,438 |
| Patent issue date |
September 2, 2014 |
| Patent expiration |
August 21, 2027, before any applicable patent-term adjustment or pediatric extension |
| Federal Circuit decision |
May 14, 2019 |
| Federal Circuit citation |
923 F.3d 1063 |
The asserted patent covered a treatment regimen using abiraterone acetate together with prednisone. The litigation therefore involved a method-of-use patent rather than only the chemical composition of abiraterone acetate.
What patent claims did BTG assert against Amneal?
BTG asserted claims directed to administering abiraterone acetate and prednisone to treat prostate cancer. The Federal Circuit identified claims 1, 6, 9, and 10 of the '438 patent as the claims at issue in the appeal. The patent was directed to the clinical regimen that became associated with Zytiga’s approved use.
The case illustrates the commercial value of a method-of-use patent in a drug product that also has an older compound patent. The original abiraterone acetate compound patent, U.S. Patent No. 5,604,213, expired in 2016. The '438 patent extended protection for the branded regimen into 2027, subject to the scope of the claims and any permissible generic label carve-out.
What did the '438 patent protect?
The relevant protection was the combination of:
- Abiraterone acetate;
- Prednisone; and
- Treatment of prostate cancer, particularly advanced or metastatic disease.
The patent did not provide broad exclusivity over every possible use of abiraterone acetate. Its commercial force depended on whether an ANDA applicant’s proposed labeling, product instructions, or expected use induced infringement of the claimed regimen.
What was Amneal’s Paragraph IV challenge?
Amneal filed an abbreviated new drug application seeking approval for generic abiraterone acetate tablets. The ANDA included a Paragraph IV certification challenging the '438 patent. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
BTG treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2). The filing triggered the Hatch-Waxman litigation and the statutory 30-month stay of FDA approval, subject to court rulings and other statutory events.
Amneal’s principal invalidity position was that the claimed abiraterone acetate and prednisone regimen would have been obvious in view of the prior art. The Federal Circuit’s decision focused on obviousness, including whether a skilled artisan would have had a reason to combine the known agents and whether the evidence established a reasonable expectation of success.
How did the district court rule?
The district court ruled for BTG on the central issues. It found that the asserted claims were not invalid for obviousness and that Amneal’s proposed product infringed the patent.
The district court’s reasoning credited evidence concerning the clinical results associated with the abiraterone acetate and prednisone combination. The record included evidence that the combination produced clinically meaningful outcomes and addressed a need in advanced prostate cancer treatment.
The court also considered whether the prior art supplied a sufficient reason to select the claimed combination from the available treatment options. The existence of prior art discussing abiraterone or corticosteroids did not, by itself, establish that the claimed regimen was obvious.
What did the Federal Circuit decide in 2019?
The Federal Circuit affirmed the district court’s judgment. The appellate court upheld the conclusion that the asserted claims were not proven obvious and affirmed the infringement determination. BTG International, 923 F.3d at 1063.
The decision is significant for three reasons.
Why did unexpected results matter?
BTG presented evidence that the combination produced better-than-expected clinical results. Unexpected results are a recognized secondary consideration of nonobviousness. The Federal Circuit accepted the district court’s treatment of the evidence as supporting patentability.
The evidence was relevant because the claimed method required the specific combination of abiraterone acetate and prednisone. A showing that each component was separately known would not necessarily establish obviousness of the claimed treatment regimen.
How did the court treat motivation to combine?
The court examined whether the prior art would have directed a skilled artisan to combine abiraterone acetate with prednisone for the claimed treatment. A generalized interest in developing prostate cancer treatments was insufficient. The challenger needed to show a reason to select the claimed combination and a reasonable expectation that it would work.
What was the infringement consequence?
Because the patent survived the validity challenge and the ANDA filing was found to infringe, Amneal could not obtain an unrestricted FDA approval that would permit launch before the relevant patent protection ended or a contractual arrangement authorized entry.
What was the Orange Book status of Zytiga?
Zytiga was protected by multiple patents and regulatory exclusivity periods at different points in its commercial life. The relevant protection included the original compound patent and later method-of-use patents.
| Patent |
General subject |
Relevance |
| U.S. 5,604,213 |
Abiraterone acetate compound |
Core compound protection; expired in 2016 |
| U.S. 8,822,438 |
Abiraterone acetate with prednisone for prostate cancer |
Principal patent in BTG v. Amneal; expiration in 2027 |
| Other Zytiga listings |
Additional use, formulation, or regulatory protection |
Scope depends on the listed use code and approved labeling |
The exact effect of a listed method patent depends on the patent claims, the FDA use code, and the generic applicant’s proposed labeling. A generic applicant may attempt a section viii statement and omit a patented indication. That strategy is viable only if the remaining label and the expected product use do not create infringement exposure.
When does abiraterone lose exclusivity?
The commercial exclusivity analysis has several dates rather than one universal expiration date.
Compound patent expiry
U.S. Patent No. 5,604,213 expired in 2016. That date removed the principal chemical-composition barrier to generic abiraterone acetate.
Method-of-use patent expiry
The '438 patent was scheduled to expire on August 21, 2027, before consideration of any applicable extension. That patent created a later barrier for the claimed abiraterone acetate and prednisone regimen.
FDA regulatory exclusivity
FDA exclusivity is separate from patent protection. Abiraterone’s regulatory exclusivity was tied to the approval history of the reference product and did not independently determine the full post-2016 market-entry timetable. Once applicable regulatory exclusivity and compound patent protection ended, ANDA applicants could pursue approval subject to remaining listed method patents.
How strong was BTG’s patent estate?
BTG’s estate was strong against a direct challenge to the claimed combination regimen because the principal patent survived appellate review. Its strength was narrower against a carefully drafted skinny-label product.
| Risk factor |
Assessment |
| Compound-patent protection |
Weak after 2016 expiration |
| Method-of-use protection |
Strong after Federal Circuit affirmance |
| Formulation protection |
Not the principal issue in this action |
| ANDA Paragraph IV exposure |
High for an uncarved label |
| Section viii carve-out potential |
Material, depending on label scope |
| Biosimilar risk |
Not applicable |
| Manufacturing patent risk |
Not central to the reported decision |
| Geographic coverage |
U.S.-specific litigation; foreign rights required separate analysis |
The estate’s main vulnerability was claim scope. A patent covering the treatment regimen can restrict generic use of the patented indication but may not prevent approval or sale for unpatented indications if the generic label is properly carved out.
What formulation patents protected Zytiga?
The reported BTG v. Amneal appeal was principally a method-of-use dispute. It did not establish a broad formulation patent ruling comparable to a case involving particle size, tablet composition, dosage form, or manufacturing process claims.
For commercial analysis, formulation and manufacturing barriers should be separated from the '438 patent. A formulation patent may cover excipients, dissolution properties, solid-state characteristics, or tablet manufacture. Those rights can create separate litigation exposure, but they should not be attributed to the BTG decision without a patent-specific record.
Did the case involve biosimilars?
No. Abiraterone acetate is a small-molecule drug regulated through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The dispute was a generic-drug Hatch-Waxman case, not a biologic patent dispute under the biosimilar pathway.
The relevant competitive threats were generic manufacturers filing ANDAs, not biosimilar applicants filing abbreviated biologics license applications.
Which companies challenged Zytiga patents?
Zytiga generated broader generic competition involving multiple ANDA applicants. Public litigation records identify challenges by companies including Amneal and other generic manufacturers. The commercial effect of each challenge depended on:
- The specific patent certifications;
- The proposed generic label;
- The timing of FDA approval;
- Any district court judgment;
- Federal Circuit appeals; and
- Settlement or license terms.
A ruling in BTG v. Amneal was not automatically dispositive of every other applicant. Each ANDA applicant had a separate infringement case, although the same patent claims and prior-art record could influence parallel litigation.
Did BTG and Amneal enter a settlement agreement?
The reported Federal Circuit decision resolves the appellate merits issues in the litigation. Public summaries of the case should not treat the appellate judgment as proof of a separate commercial settlement unless a settlement agreement or dismissal order is specifically identified in the docket.
The practical outcome was that Amneal faced an enforceable patent judgment covering the claimed treatment regimen. Any launch before the '438 patent’s scheduled expiration would have required a legal or contractual basis, such as a successful label carve-out, a license, or settlement-authorized entry.
What generic launch scenarios existed for Amneal?
Amneal’s potential launch paths fell into four categories.
Launch after patent expiry
The lowest litigation-risk path was entry after expiration of the relevant method patent and any applicable exclusivity period.
Skinny-label launch
Amneal could seek approval with patented indications removed from the label. This strategy would reduce, but not eliminate, infringement risk. Courts assess the proposed label and the surrounding evidence of intended use.
Settlement-authorized launch
A settlement could establish an agreed entry date earlier than patent expiration. The commercial value of such a settlement would depend on the negotiated launch date, royalties, supply terms, and restrictions.
Successful invalidity or noninfringement appeal
Amneal could have pursued market entry by overturning the district court judgment. The Federal Circuit outcome closed that route for the claims and issues affirmed in the appeal.
What was the revenue exposure from the litigation?
Zytiga was a major oncology product for Janssen and its commercial partners. The principal revenue exposure was the loss of branded abiraterone sales following generic entry, not merely the cost of defending the patent.
The compound patent’s 2016 expiration created substantial generic pressure. The '438 patent delayed or complicated unrestricted generic competition for the prednisone-combination regimen. The financial impact depended on:
- The percentage of Zytiga prescriptions covered by the patented indication;
- Generic substitution rates;
- The timing and number of generic entrants;
- Whether applicants launched with carved-out labels;
- Settlement-authorized entry dates; and
- Net price erosion after launch.
A later method patent can preserve revenue only to the extent that it blocks practical generic substitution. If generics can obtain approval for commercially important unpatented uses, the brand may still face substantial erosion before method-patent expiration.
What litigation status and precedent does the case create?
The controlling appellate result is that the asserted '438 patent claims survived Amneal’s obviousness challenge and remained enforceable against the proposed generic product. The case is useful precedent on:
- Obviousness of a drug combination regimen;
- The evidentiary value of unexpected clinical results;
- The need for a specific motivation to combine prior-art teachings;
- ANDA infringement under section 271(e)(2); and
- The commercial importance of method-of-use patents after compound-patent expiry.
The decision does not establish that every abiraterone generic is barred through 2027. Its effect depends on the generic applicant’s ANDA, label, patent certifications, and any separate litigation outcome.
Key Takeaways
- BTG International v. Amneal concerned generic abiraterone acetate for Zytiga.
- The principal patent was U.S. Patent No. 8,822,438.
- The patent claimed treatment with abiraterone acetate in combination with prednisone.
- Amneal filed a Paragraph IV challenge through its ANDA.
- The district court found the asserted claims valid and infringed.
- The Federal Circuit affirmed in 2019.
- The '438 patent was scheduled to expire on August 21, 2027.
- The case involved a small-molecule generic, not a biosimilar.
- The strongest remaining risk to unrestricted generic entry was the method-of-use patent.
- A skinny-label strategy could materially change the infringement and launch analysis.
- The ruling did not automatically resolve every other Zytiga patent case or every generic applicant’s launch rights.
FAQs About BTG International v. Amneal
What was the case number for BTG v. Amneal?
The district court case was BTG International Limited v. Amneal Pharmaceuticals LLC, No. 2:15-cv-05909, in the U.S. District Court for the District of New Jersey.
What was the Federal Circuit citation for the case?
The appellate decision is reported at 923 F.3d 1063 (Fed. Cir. 2019).
Which Zytiga patent was litigated against Amneal?
The principal patent was U.S. Patent No. 8,822,438, covering treatment of prostate cancer with abiraterone acetate and prednisone.
Did the case concern abiraterone acetate tablets or a biologic?
It concerned abiraterone acetate tablets, a small-molecule generic drug regulated under the ANDA pathway.
Could Amneal launch a generic with a carved-out label?
A carved-out label could potentially reduce infringement exposure, but the outcome would depend on the precise approved labeling, the patented indication, the ANDA certification, and the court’s application of induced-infringement principles.
References
-
BTG International Ltd. v. Amneal Pharmaceuticals LLC, 923 F.3d 1063 (Fed. Cir. 2019).
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Patent No. 5,604,213. (1997). Abiraterone, derivatives thereof, and use thereof as a medicament.
-
U.S. Patent No. 8,822,438. (2014). Treatment of cancer with abiraterone acetate.
-
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
-
35 U.S.C. § 271(e)(2).
